Sagimet Biosciences will present at three investor conferences in March 2026, discussing clinical developments in metabolic therapies.
Quiver AI Summary
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing therapies for dysfunctional metabolic and fibrotic pathways, announced participation in three investor conferences in March 2026. The conferences include the TD Cowen 46th Annual Health Care Conference in Boston on March 2, the Leerink Global Healthcare Conference in Miami on March 9, and the Citizens Life Sciences Conference in Miami on March 10. Key discussions will be available via live stream on Sagimet's website, with archived replays for 90 days. Sagimet's lead product, denifanstat, has shown positive results in clinical trials for metabolic disorders and acne, and the company is also developing another drug, TVB-3567, for acne treatment. For more information, visit their website.
Potential Positives
- Sagimet Biosciences is participating in three key investor conferences, enhancing visibility and engagement with potential investors.
- The company has successfully met all primary and secondary endpoints in its clinical trials, which may bolster investor confidence in its product pipeline.
- Sagimet is in advanced clinical stages with its product denifanstat, indicating progress and potential for future market introduction.
- The development of additional therapeutics, such as TVB-3567, demonstrates continuous innovation and expansion within their pipeline, signaling growth potential.
Potential Negatives
- Participation in investor conferences may indicate a need for increased visibility or support from investors, which could suggest underlying concerns about investor confidence in the company's growth prospects.
- The emphasis on upcoming conferences without significant new data or updates on product pipelines might imply a lack of substantial progress or newsworthy advancements in their research and development efforts.
- Recent clinical trials outcomes are mentioned, yet the lack of detailed information on the next steps or specific timelines may raise doubts about the future commercial viability of their product candidates.
FAQ
What investor conferences will Sagimet Biosciences attend in March 2026?
Sagimet Biosciences will participate in the TD Cowen, Leerink Global Healthcare, and Citizens Life Sciences conferences in March 2026.
Where can I find the schedule for Sagimet's investor conferences?
The schedule for Sagimet's conferences is available on their website, under the Investors & Media section.
What is denifanstat and its significance in clinical trials?
Denifanstat is an oral FASN inhibitor that met primary endpoints in Phase 2b and Phase 3 clinical trials for MASH and acne.
How can I access recordings of Sagimet's fireside chats?
The fireside chats will be available on Sagimet's website for 90 days after the live events.
What are the future development plans for Sagimet's drugs?
Sagimet plans to further develop denifanstat and TVB-3567 for conditions like cirrhosis and acne in upcoming clinical trials.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SGMT Insider Trading Activity
$SGMT insiders have traded $SGMT stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $SGMT stock by insiders over the last 6 months:
- GEORGE KEMBLE (Executive Chairman) sold 37,688 shares for an estimated $289,979
- DAVID HAPPEL (President & CEO) sold 12,101 shares for an estimated $64,864
- EDUARDO BRUNO MARTINS (Chief Medical Officer) sold 3,640 shares for an estimated $19,511
- ELIZABETH ROZEK (Chief Legal & Admin. Officer) sold 2,622 shares for an estimated $14,054
- THIERRY CHAUCHE (Chief Financial Officer) sold 1,312 shares for an estimated $7,032
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SGMT Hedge Fund Activity
We have seen 55 institutional investors add shares of $SGMT stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AFFINITY ASSET ADVISORS, LLC added 798,245 shares (+228.1%) to their portfolio in Q4 2025, for an estimated $4,725,610
- MARSHALL WACE, LLP added 780,446 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,620,240
- SCHONFELD STRATEGIC ADVISORS LLC removed 523,774 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,100,742
- WOODLINE PARTNERS LP removed 500,414 shares (-33.3%) from their portfolio in Q4 2025, for an estimated $2,962,450
- READYSTATE ASSET MANAGEMENT LP removed 325,359 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,926,125
- HUDSON BAY CAPITAL MANAGEMENT LP added 304,472 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,802,474
- PALE FIRE CAPITAL SE added 221,875 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,313,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SGMT Analyst Ratings
Wall Street analysts have issued reports on $SGMT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/14/2025
- Clear Street issued a "Buy" rating on 10/22/2025
- Canaccord Genuity issued a "Buy" rating on 10/02/2025
To track analyst ratings and price targets for $SGMT, check out Quiver Quantitative's $SGMT forecast page.
$SGMT Price Targets
Multiple analysts have issued price targets for $SGMT recently. We have seen 6 analysts offer price targets for $SGMT in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $29.0 on 02/03/2026
- Seamus Fernandez from Guggenheim set a target price of $27.0 on 02/03/2026
- Eliana Merle from Barclays set a target price of $8.0 on 01/28/2026
- Jonathan Wolleben from Citizens set a target price of $35.0 on 11/14/2025
- Kaveri Pohlman from Clear Street set a target price of $29.0 on 10/22/2025
- Edward Nash from Canaccord Genuity set a target price of $28.0 on 10/02/2025
Full Release
SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences.
- TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 2, 2026, with a fireside chat at 1:10pm ET (link here ).
- Leerink Global Healthcare Conference in Miami, FL, on March 9, 2026, with a fireside chat at 1pm ET (link here ).
-
The Citizens Life Sciences Conference in Miami, FL, on March 10, 2026, with a fireside chat at 10:45am ET.
The TD Cowen and Leerink fireside chats will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com , with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial and is planned to be developed for cirrhotic patients living with F4-stage MASH. TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit www.sagimet.com .
Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
Media Contact:
Maggie Whitney
LifeSci Communications
[email protected]
